Australia's DorsaVi Ltd. has taken measures to cut costs, which will reduce cash outflows from operating activities by 30% to 40% compared to the first half of 2019.
The measures include reducing staff in corporate and support services and focusing on existing product portfolio rather than developing additional products.
In addition, the Kew, Victoria-based company plans to prioritize increasing direct sales capability in the U.S. workplace and clinical market.
DorsaVi's said its senior management is taking a voluntary reduction in salaries, with CEO Andrew Ronchi agreeing to reduce his pay and benefits from $310,000 to $221,500.
Further, the company's nonexecutive directors have agreed, subject to shareholder approval, to accept stock options as their fees starting from March 1.
DorsaVi makes wearable sensors to measure movement and muscle activation for use in treating sports injuries and assist in athletic training and recovery.